apfcbAPFCB eNewscoAPFCB News Volume 1, Issue 1MultidisciplinaryEnglishJan-Jun, 2022NNY20220930ArticlesCSF biomarkers and their role in Alzheimer’s diseaseEnglishY5253SamanthaYeoh1EnglishN10.62772/APFCB-News.2022.1.4Amid the continued ageing of the global population, Alzheimer’s disease is a serious and rapidly growing public health concern. The Asia Pacific region alone is estimated to have over 23 million cases today, and that figure is projected to be more than 70 million cases by 2050 [1]. While much attention is currently on a new therapeutic intervention recently approved by the FDA, clinical lab diagnostics will also be essential for helping to manage this growing crisis.Englishhttps://apfcb.org/APFCB_News/abstract?id=34References16191) Dementia in the Asia Pacific Region 2014 Report, Alzheimerand;#39;s Disease International.2) Buchhave, P. et al. (2012) Cerebrospinal Fluid Levels of and;beta;-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia. Archives of General Psychiatry, 69(1), pp98.3) Olsson, B., et al. (2016) CSF and blood biomarkers for the diagnosis of Alzheimerand;rsquo;s disease: a systematic review and meta-analysis. The Lancet Neurology, 15, pp673- 684.4) Alzheimerand;#39;s Disease Diagnostic Guidelines, Dementia Resources for Health Professionals, National Institute of Health.5) The Alzheimerand;#39;s Association QC program for CSF and blood biomarkers.6) Dubois, B. et al. (2016) Timely diagnosis for Alzheimerand;#39;s Disease, A Literature Review on Benefits and Challenges. Journal of Alzheimerand;#39;s Disease 49, pp617-631.7) Lleo, A. et al. (2014) Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nature Reviews Neurology, 11, pp41-55.8) Horgan, D. et al. (2020) Biomarker Testing: Piercing the Fog of Alzheimerand;#39;s and Related Dementia. Biomedicine Hub.